nodes	percent_of_prediction	percent_of_DWPC	metapath
Bismuth Subsalicylate—Localized exfoliation—Bleomycin—lymphatic system cancer	0.0502	0.0502	CcSEcCtD
Bismuth Subsalicylate—Extravasation—Teniposide—lymphatic system cancer	0.0241	0.0241	CcSEcCtD
Bismuth Subsalicylate—Epigastric pain—Mitoxantrone—lymphatic system cancer	0.0227	0.0227	CcSEcCtD
Bismuth Subsalicylate—Hearing impaired—Fludarabine—lymphatic system cancer	0.0194	0.0194	CcSEcCtD
Bismuth Subsalicylate—Phlebitis—Teniposide—lymphatic system cancer	0.0177	0.0177	CcSEcCtD
Bismuth Subsalicylate—Burning sensation—Carmustine—lymphatic system cancer	0.017	0.017	CcSEcCtD
Bismuth Subsalicylate—Oesophagitis—Fludarabine—lymphatic system cancer	0.0169	0.0169	CcSEcCtD
Bismuth Subsalicylate—Phlebitis—Fludarabine—lymphatic system cancer	0.0156	0.0156	CcSEcCtD
Bismuth Subsalicylate—Extravasation—Bleomycin—lymphatic system cancer	0.0155	0.0155	CcSEcCtD
Bismuth Subsalicylate—Deafness—Fludarabine—lymphatic system cancer	0.015	0.015	CcSEcCtD
Bismuth Subsalicylate—Extravasation—Carmustine—lymphatic system cancer	0.0135	0.0135	CcSEcCtD
Bismuth Subsalicylate—Erythema multiforme—Mechlorethamine—lymphatic system cancer	0.0135	0.0135	CcSEcCtD
Bismuth Subsalicylate—Tinnitus—Mechlorethamine—lymphatic system cancer	0.0133	0.0133	CcSEcCtD
Bismuth Subsalicylate—Extravasation—Vincristine—lymphatic system cancer	0.0129	0.0129	CcSEcCtD
Bismuth Subsalicylate—Skin exfoliation—Bleomycin—lymphatic system cancer	0.0129	0.0129	CcSEcCtD
Bismuth Subsalicylate—Extravasation—Mitoxantrone—lymphatic system cancer	0.0126	0.0126	CcSEcCtD
Bismuth Subsalicylate—Phlebitis—Bleomycin—lymphatic system cancer	0.0114	0.0114	CcSEcCtD
Bismuth Subsalicylate—Skin exfoliation—Carmustine—lymphatic system cancer	0.0113	0.0113	CcSEcCtD
Bismuth Subsalicylate—Infection—Mechlorethamine—lymphatic system cancer	0.0101	0.0101	CcSEcCtD
Bismuth Subsalicylate—Phlebitis—Carmustine—lymphatic system cancer	0.00995	0.00995	CcSEcCtD
Bismuth Subsalicylate—Ecchymosis—Mitoxantrone—lymphatic system cancer	0.00993	0.00993	CcSEcCtD
Bismuth Subsalicylate—Epistaxis—Fludarabine—lymphatic system cancer	0.00974	0.00974	CcSEcCtD
Bismuth Subsalicylate—Anorexia—Mechlorethamine—lymphatic system cancer	0.00969	0.00969	CcSEcCtD
Bismuth Subsalicylate—Phlebitis—Mitoxantrone—lymphatic system cancer	0.00925	0.00925	CcSEcCtD
Bismuth Subsalicylate—Deafness—Vincristine—lymphatic system cancer	0.00915	0.00915	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Mechlorethamine—lymphatic system cancer	0.00883	0.00883	CcSEcCtD
Bismuth Subsalicylate—Erythema multiforme—Fludarabine—lymphatic system cancer	0.00876	0.00876	CcSEcCtD
Bismuth Subsalicylate—Hyponatraemia—Carmustine—lymphatic system cancer	0.00861	0.00861	CcSEcCtD
Bismuth Subsalicylate—Hyponatraemia—Vincristine—lymphatic system cancer	0.00822	0.00822	CcSEcCtD
Bismuth Subsalicylate—Hyponatraemia—Mitoxantrone—lymphatic system cancer	0.008	0.008	CcSEcCtD
Bismuth Subsalicylate—Burning sensation—Methotrexate—lymphatic system cancer	0.00787	0.00787	CcSEcCtD
Bismuth Subsalicylate—Lung disorder—Methotrexate—lymphatic system cancer	0.00773	0.00773	CcSEcCtD
Bismuth Subsalicylate—Confusional state—Teniposide—lymphatic system cancer	0.00755	0.00755	CcSEcCtD
Bismuth Subsalicylate—Oedema—Teniposide—lymphatic system cancer	0.00749	0.00749	CcSEcCtD
Bismuth Subsalicylate—Infection—Teniposide—lymphatic system cancer	0.00744	0.00744	CcSEcCtD
Bismuth Subsalicylate—Abdominal pain upper—Mitoxantrone—lymphatic system cancer	0.00728	0.00728	CcSEcCtD
Bismuth Subsalicylate—Pruritus—Mechlorethamine—lymphatic system cancer	0.00719	0.00719	CcSEcCtD
Bismuth Subsalicylate—Anorexia—Teniposide—lymphatic system cancer	0.00714	0.00714	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00695	0.00695	CcSEcCtD
Bismuth Subsalicylate—Confusional state—Fludarabine—lymphatic system cancer	0.00664	0.00664	CcSEcCtD
Bismuth Subsalicylate—Oedema—Fludarabine—lymphatic system cancer	0.00658	0.00658	CcSEcCtD
Bismuth Subsalicylate—Infection—Fludarabine—lymphatic system cancer	0.00654	0.00654	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Teniposide—lymphatic system cancer	0.00651	0.00651	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Mechlorethamine—lymphatic system cancer	0.00646	0.00646	CcSEcCtD
Bismuth Subsalicylate—Rash—Mechlorethamine—lymphatic system cancer	0.00641	0.00641	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Mechlorethamine—lymphatic system cancer	0.0064	0.0064	CcSEcCtD
Bismuth Subsalicylate—Anorexia—Fludarabine—lymphatic system cancer	0.00628	0.00628	CcSEcCtD
Bismuth Subsalicylate—Extravasation—Methotrexate—lymphatic system cancer	0.00627	0.00627	CcSEcCtD
Bismuth Subsalicylate—Weight increased—Mitoxantrone—lymphatic system cancer	0.00627	0.00627	CcSEcCtD
Bismuth Subsalicylate—Feeling abnormal—Teniposide—lymphatic system cancer	0.00617	0.00617	CcSEcCtD
Bismuth Subsalicylate—Drowsiness—Mitoxantrone—lymphatic system cancer	0.00614	0.00614	CcSEcCtD
Bismuth Subsalicylate—Nausea—Mechlorethamine—lymphatic system cancer	0.00604	0.00604	CcSEcCtD
Bismuth Subsalicylate—Urticaria—Teniposide—lymphatic system cancer	0.00595	0.00595	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Teniposide—lymphatic system cancer	0.00592	0.00592	CcSEcCtD
Bismuth Subsalicylate—Erythema—Bleomycin—lymphatic system cancer	0.00592	0.00592	CcSEcCtD
Bismuth Subsalicylate—Hallucination—Carmustine—lymphatic system cancer	0.0059	0.0059	CcSEcCtD
Bismuth Subsalicylate—Dyspepsia—Fludarabine—lymphatic system cancer	0.0058	0.0058	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Fludarabine—lymphatic system cancer	0.00572	0.00572	CcSEcCtD
Bismuth Subsalicylate—Hallucination—Vincristine—lymphatic system cancer	0.00563	0.00563	CcSEcCtD
Bismuth Subsalicylate—Pain—Fludarabine—lymphatic system cancer	0.00563	0.00563	CcSEcCtD
Bismuth Subsalicylate—Constipation—Fludarabine—lymphatic system cancer	0.00563	0.00563	CcSEcCtD
Bismuth Subsalicylate—Hepatitis—Mitoxantrone—lymphatic system cancer	0.00551	0.00551	CcSEcCtD
Bismuth Subsalicylate—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00543	0.00543	CcSEcCtD
Bismuth Subsalicylate—Pruritus—Teniposide—lymphatic system cancer	0.0053	0.0053	CcSEcCtD
Bismuth Subsalicylate—Skin exfoliation—Methotrexate—lymphatic system cancer	0.00522	0.00522	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Fludarabine—lymphatic system cancer	0.00521	0.00521	CcSEcCtD
Bismuth Subsalicylate—Erythema—Carmustine—lymphatic system cancer	0.00516	0.00516	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Teniposide—lymphatic system cancer	0.00513	0.00513	CcSEcCtD
Bismuth Subsalicylate—Ecchymosis—Methotrexate—lymphatic system cancer	0.00495	0.00495	CcSEcCtD
Bismuth Subsalicylate—Confusional state—Bleomycin—lymphatic system cancer	0.00487	0.00487	CcSEcCtD
Bismuth Subsalicylate—Oedema—Bleomycin—lymphatic system cancer	0.00483	0.00483	CcSEcCtD
Bismuth Subsalicylate—Erythema—Mitoxantrone—lymphatic system cancer	0.0048	0.0048	CcSEcCtD
Bismuth Subsalicylate—Infection—Bleomycin—lymphatic system cancer	0.0048	0.0048	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Teniposide—lymphatic system cancer	0.00476	0.00476	CcSEcCtD
Bismuth Subsalicylate—Rash—Teniposide—lymphatic system cancer	0.00472	0.00472	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Teniposide—lymphatic system cancer	0.00472	0.00472	CcSEcCtD
Bismuth Subsalicylate—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.0047	0.0047	CcSEcCtD
Bismuth Subsalicylate—Headache—Teniposide—lymphatic system cancer	0.00469	0.00469	CcSEcCtD
Bismuth Subsalicylate—Pruritus—Fludarabine—lymphatic system cancer	0.00466	0.00466	CcSEcCtD
Bismuth Subsalicylate—Anorexia—Bleomycin—lymphatic system cancer	0.0046	0.0046	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Fludarabine—lymphatic system cancer	0.00451	0.00451	CcSEcCtD
Bismuth Subsalicylate—Nausea—Teniposide—lymphatic system cancer	0.00445	0.00445	CcSEcCtD
Bismuth Subsalicylate—Confusional state—Carmustine—lymphatic system cancer	0.00425	0.00425	CcSEcCtD
Bismuth Subsalicylate—Oedema—Carmustine—lymphatic system cancer	0.00421	0.00421	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Bleomycin—lymphatic system cancer	0.0042	0.0042	CcSEcCtD
Bismuth Subsalicylate—Infection—Carmustine—lymphatic system cancer	0.00419	0.00419	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Fludarabine—lymphatic system cancer	0.00419	0.00419	CcSEcCtD
Bismuth Subsalicylate—Rash—Fludarabine—lymphatic system cancer	0.00415	0.00415	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Fludarabine—lymphatic system cancer	0.00415	0.00415	CcSEcCtD
Bismuth Subsalicylate—Pain—Bleomycin—lymphatic system cancer	0.00413	0.00413	CcSEcCtD
Bismuth Subsalicylate—Headache—Fludarabine—lymphatic system cancer	0.00412	0.00412	CcSEcCtD
Bismuth Subsalicylate—Lethargy—Methotrexate—lymphatic system cancer	0.00405	0.00405	CcSEcCtD
Bismuth Subsalicylate—Oedema—Vincristine—lymphatic system cancer	0.00402	0.00402	CcSEcCtD
Bismuth Subsalicylate—Anorexia—Carmustine—lymphatic system cancer	0.00402	0.00402	CcSEcCtD
Bismuth Subsalicylate—Infection—Vincristine—lymphatic system cancer	0.004	0.004	CcSEcCtD
Bismuth Subsalicylate—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00398	0.00398	CcSEcCtD
Bismuth Subsalicylate—Confusional state—Mitoxantrone—lymphatic system cancer	0.00395	0.00395	CcSEcCtD
Bismuth Subsalicylate—Oedema—Mitoxantrone—lymphatic system cancer	0.00392	0.00392	CcSEcCtD
Bismuth Subsalicylate—Nausea—Fludarabine—lymphatic system cancer	0.00391	0.00391	CcSEcCtD
Bismuth Subsalicylate—Infection—Mitoxantrone—lymphatic system cancer	0.00389	0.00389	CcSEcCtD
Bismuth Subsalicylate—Urticaria—Bleomycin—lymphatic system cancer	0.00384	0.00384	CcSEcCtD
Bismuth Subsalicylate—Anorexia—Vincristine—lymphatic system cancer	0.00383	0.00383	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Bleomycin—lymphatic system cancer	0.00382	0.00382	CcSEcCtD
Bismuth Subsalicylate—Somnolence—Carmustine—lymphatic system cancer	0.00375	0.00375	CcSEcCtD
Bismuth Subsalicylate—Anorexia—Mitoxantrone—lymphatic system cancer	0.00373	0.00373	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Carmustine—lymphatic system cancer	0.00366	0.00366	CcSEcCtD
Bismuth Subsalicylate—Pain—Carmustine—lymphatic system cancer	0.0036	0.0036	CcSEcCtD
Bismuth Subsalicylate—Constipation—Carmustine—lymphatic system cancer	0.0036	0.0036	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Vincristine—lymphatic system cancer	0.0035	0.0035	CcSEcCtD
Bismuth Subsalicylate—Somnolence—Mitoxantrone—lymphatic system cancer	0.00348	0.00348	CcSEcCtD
Bismuth Subsalicylate—Feeling abnormal—Carmustine—lymphatic system cancer	0.00347	0.00347	CcSEcCtD
Bismuth Subsalicylate—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00345	0.00345	CcSEcCtD
Bismuth Subsalicylate—Pain—Vincristine—lymphatic system cancer	0.00344	0.00344	CcSEcCtD
Bismuth Subsalicylate—Constipation—Vincristine—lymphatic system cancer	0.00344	0.00344	CcSEcCtD
Bismuth Subsalicylate—Asthma—Methotrexate—lymphatic system cancer	0.00343	0.00343	CcSEcCtD
Bismuth Subsalicylate—Pruritus—Bleomycin—lymphatic system cancer	0.00342	0.00342	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.00341	0.00341	CcSEcCtD
Bismuth Subsalicylate—Pain—Mitoxantrone—lymphatic system cancer	0.00335	0.00335	CcSEcCtD
Bismuth Subsalicylate—Constipation—Mitoxantrone—lymphatic system cancer	0.00335	0.00335	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Carmustine—lymphatic system cancer	0.00333	0.00333	CcSEcCtD
Bismuth Subsalicylate—Abdominal discomfort—Methotrexate—lymphatic system cancer	0.00329	0.00329	CcSEcCtD
Bismuth Subsalicylate—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00323	0.00323	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Vincristine—lymphatic system cancer	0.00318	0.00318	CcSEcCtD
Bismuth Subsalicylate—Urticaria—Mitoxantrone—lymphatic system cancer	0.00311	0.00311	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.0031	0.0031	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Bleomycin—lymphatic system cancer	0.00307	0.00307	CcSEcCtD
Bismuth Subsalicylate—Drowsiness—Methotrexate—lymphatic system cancer	0.00306	0.00306	CcSEcCtD
Bismuth Subsalicylate—Rash—Bleomycin—lymphatic system cancer	0.00304	0.00304	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Bleomycin—lymphatic system cancer	0.00304	0.00304	CcSEcCtD
Bismuth Subsalicylate—Epistaxis—Methotrexate—lymphatic system cancer	0.00289	0.00289	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Carmustine—lymphatic system cancer	0.00288	0.00288	CcSEcCtD
Bismuth Subsalicylate—Nausea—Bleomycin—lymphatic system cancer	0.00287	0.00287	CcSEcCtD
Bismuth Subsalicylate—Dizziness—Carmustine—lymphatic system cancer	0.00279	0.00279	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Vincristine—lymphatic system cancer	0.00275	0.00275	CcSEcCtD
Bismuth Subsalicylate—Hepatitis—Methotrexate—lymphatic system cancer	0.00275	0.00275	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.00268	0.00268	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Carmustine—lymphatic system cancer	0.00268	0.00268	CcSEcCtD
Bismuth Subsalicylate—Dizziness—Vincristine—lymphatic system cancer	0.00266	0.00266	CcSEcCtD
Bismuth Subsalicylate—Rash—Carmustine—lymphatic system cancer	0.00266	0.00266	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Carmustine—lymphatic system cancer	0.00265	0.00265	CcSEcCtD
Bismuth Subsalicylate—Headache—Carmustine—lymphatic system cancer	0.00264	0.00264	CcSEcCtD
Bismuth Subsalicylate—Erythema multiforme—Methotrexate—lymphatic system cancer	0.0026	0.0026	CcSEcCtD
Bismuth Subsalicylate—Tinnitus—Methotrexate—lymphatic system cancer	0.00256	0.00256	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Vincristine—lymphatic system cancer	0.00256	0.00256	CcSEcCtD
Bismuth Subsalicylate—Rash—Vincristine—lymphatic system cancer	0.00254	0.00254	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Vincristine—lymphatic system cancer	0.00253	0.00253	CcSEcCtD
Bismuth Subsalicylate—Headache—Vincristine—lymphatic system cancer	0.00252	0.00252	CcSEcCtD
Bismuth Subsalicylate—Nausea—Carmustine—lymphatic system cancer	0.0025	0.0025	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Mitoxantrone—lymphatic system cancer	0.00249	0.00249	CcSEcCtD
Bismuth Subsalicylate—Rash—Mitoxantrone—lymphatic system cancer	0.00247	0.00247	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00247	0.00247	CcSEcCtD
Bismuth Subsalicylate—Headache—Mitoxantrone—lymphatic system cancer	0.00245	0.00245	CcSEcCtD
Bismuth Subsalicylate—Erythema—Methotrexate—lymphatic system cancer	0.00239	0.00239	CcSEcCtD
Bismuth Subsalicylate—Nausea—Vincristine—lymphatic system cancer	0.00239	0.00239	CcSEcCtD
Bismuth Subsalicylate—Dysgeusia—Methotrexate—lymphatic system cancer	0.00234	0.00234	CcSEcCtD
Bismuth Subsalicylate—Nausea—Mitoxantrone—lymphatic system cancer	0.00233	0.00233	CcSEcCtD
Bismuth Subsalicylate—Confusional state—Methotrexate—lymphatic system cancer	0.00197	0.00197	CcSEcCtD
Bismuth Subsalicylate—Infection—Methotrexate—lymphatic system cancer	0.00194	0.00194	CcSEcCtD
Bismuth Subsalicylate—Anorexia—Methotrexate—lymphatic system cancer	0.00186	0.00186	CcSEcCtD
Bismuth Subsalicylate—Somnolence—Methotrexate—lymphatic system cancer	0.00174	0.00174	CcSEcCtD
Bismuth Subsalicylate—Dyspepsia—Methotrexate—lymphatic system cancer	0.00172	0.00172	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Methotrexate—lymphatic system cancer	0.0017	0.0017	CcSEcCtD
Bismuth Subsalicylate—Pain—Methotrexate—lymphatic system cancer	0.00167	0.00167	CcSEcCtD
Bismuth Subsalicylate—Feeling abnormal—Methotrexate—lymphatic system cancer	0.00161	0.00161	CcSEcCtD
Bismuth Subsalicylate—Urticaria—Methotrexate—lymphatic system cancer	0.00155	0.00155	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Methotrexate—lymphatic system cancer	0.00154	0.00154	CcSEcCtD
Bismuth Subsalicylate—Pruritus—Methotrexate—lymphatic system cancer	0.00138	0.00138	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Methotrexate—lymphatic system cancer	0.00134	0.00134	CcSEcCtD
Bismuth Subsalicylate—Dizziness—Methotrexate—lymphatic system cancer	0.00129	0.00129	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Methotrexate—lymphatic system cancer	0.00124	0.00124	CcSEcCtD
Bismuth Subsalicylate—Rash—Methotrexate—lymphatic system cancer	0.00123	0.00123	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Methotrexate—lymphatic system cancer	0.00123	0.00123	CcSEcCtD
Bismuth Subsalicylate—Headache—Methotrexate—lymphatic system cancer	0.00122	0.00122	CcSEcCtD
Bismuth Subsalicylate—Nausea—Methotrexate—lymphatic system cancer	0.00116	0.00116	CcSEcCtD
